San Diego-based Ambit Biosciences said today that it has named Michael A. Martino as its new President and CEO. Ambit, which is developing small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications, said that Martino replaces Alan Lewis. Martino was previously at CareFusion, Arzeda Corp, Sonus Pharmaceuticals, and Mallinckrodt.
Top NewsWednesday, November 16, 2011
Ambit Biosciences Names CEO